United States set
Menu Shopping cart $0 Search
Manufactured by BioVendor

Plasma Renin Activity ELISA

  • Regulatory status:RUO
  • Type:Competitive ELISA
  • Other names:Angiotensinogenase, REN
  • Species:Human
Cat. No. Size Price

RCD032R 96 wells (1 kit) $469,84
PubMed Product Details
Technical Data


Competitive ELISA


For the quantitative determination of Plasma Renin Activity (PRA) in human plasma by an enzyme immunoassay. For research use only.



Sample Requirements

50 μl/well


On blue ice packs. Upon receipt, store the product at the temperature recommended below.


Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Range

0.2-60 ng/ml

Limit of Detection

0.14 ng/ml

Intra-assay (Within-Run)

CV = 7.2%

Inter-assay (Run-to-Run)

CV = 5.68%



  • RUO
  • calibration range 0.2 - 60 ng/ml
  • limit of detection 0.14 ng/ml
  • controls
  • intra-assay CV = 7.2%
  • inter-assay CV = 5.68%
  • the calibrators are calibrated against the World Health Organization reference reagent NIBSC code 86/536.

Research topic

Blood pressure regulation and NO metabolism, Cardiovascular disease, Diabetology - Other Relevant Products, Renal disease


Measurement of PRA is important for the clinical evaluation of hypertensive patients. In particular, determination of plasma renin activity can help in the diagnosis of primary hyperaldosteronism (5–13% of hypertensive cases) and assist in the therapy and management of other forms of hypertension. PRA, in contrast to the determination of renin concentration, is a more accurate indicator of primary hyperaldosteronism (PHA), because of several reasons: 1. PRA is the expression of the rate of Ang-I formation through the enzymatic action of renin on its substrate, angiotensinogen, therefore PRA depends not only on renin concentration but also on the concentration of angiotensinogen which is ignored in the renin concentration assay; 2. Plasma renin concentration assay does not ensure sensitivity in low renin states, while the sensitivity of the PRA assay can be enhanced by increasing the incubation time during the generation step (Sealey et al., 2005), 3. When an inhibitor is bound to the renin active site PRA is inhibited, whereas the presence of the inhibitor does not affect the recognition of renin by currently available immunoassays, therefore total renin concentration does not always correlate with plasma renin activity (Campbell et al., 2009). Renin liberates angiotensin-I from angiotensinogen. Angiotensin-I is transformed to angiotensin-II largely in pulmonary circulation by angiotensin converting enzyme (ACE). Angiotensin-II raises blood pressure by direct arteriolar vasoconstriction, promoting sodium retention, and stimulating the secretion of aldosterone from the adrenal cortex. Aldosterone also exerts an effect to restore sodium balance and lift arterial pressure. Accurate measurement of the concentration of circulating angiotensin-II is challenging because of its instability in blood samples. Aldosterone concentration can be easily determined using the BioVendor immunoassay kit (RCD030R).

Related Products Docs